TickerTalks
Browse all tickers →
TickerTalks›$RGEN
RGRGEN

Repligen Corporation

$RGEN·$8.1B·Medical - Instruments & Supplies·Healthcare
$147.25-0.9%YTD-10.0%1Y+18.7%
Mentions · last 7 days
2026-07-11: 0 posts2026-07-12: 0 posts2026-07-13: 1 posts2026-07-14: 0 posts2026-07-15: 1 posts2026-07-16: 1 posts2026-07-17: 0 posts4-4%
Price updated 4h ago·X counts updated 4h ago
RGRGEN
$RGENRepligen Corporation
$147.25-0.88%4 posts-4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $RGEN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-07-16

The move is getting stronger, with heavier trading behind it.

Repligen's bioprocessing revenue grew 15% year-over-year and its four straight EPS beats set up the August 4 print.

Repligen Corporation provides specialty bioprocessing filtration, chromatography, and analytics products to biopharmaceutical manufacturers, $8.14B market cap, with Q2 2026 earnings due 2026-08-04.

  • Q1 revenue was $194M, up 14.8% year-over-year with sequential -1.8% (seasonal Q1 dip), and EPS $0.48 topped the $0.38 consensus by 26.3% — the fourth consecutive positive surprise with magnitudes stepping from -7.5% up to 26.3%.
  • Gross margin sits at 50.3%, operating margin 8.8%, and trailing return on invested capital of 2.2% — solid bioprocessing economics with room to expand as utilization scales.
  • Consensus models 2026 revenue at $822M rising to $943M in 2027 and $1.08B in 2028, with EPS growing from $2.00 to $2.58 to $3.28 — the 134x trailing multiple discounts the growth arc.
  • A July 7 24/7 Wall St piece included RGEN in Best Wall Street Analyst Research Calls — analyst endorsement.
  • A June 25 GuruFocus note flagged the 4.9% gain and framed GF Value at $175.89 versus current $145.23.
  • Insider activity: June 25 CFO Jason Garland S-Sale of 733 shares at $145 for $106K — modest diversification.
  • The stock is up 25% over twelve months but down 9% year-to-date, at 63% of the 52-week range and 16% above the 50-day.

The setup is a specialty bioprocessing operator with EPS-beat execution — August 4 tests fiscal 2026 re-rating.

What to watch: August 4 Q2 earnings — bioprocessing revenue growth versus the +14.8% Q1 pace, gross-margin trajectory versus the 50.3% base, operating-margin trajectory (currently 8.8%), and full-year 2026 revenue guide versus the $822M consensus. Commentary on biopharmaceutical customer-order backlog and China market recovery are qualitative signals.

On the calendar: 2026-08-04 Q2 2026 earnings; revenue growth and operating-margin trajectory drive the print.

Read the AI verdict + X sentiment for $RGEN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes bioprocessing filtration, chromatography, and fluid management components used in biologic drug manufacturing.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $RGEN.

Medical - Instruments & Supplies · Healthcare

No material change from last week — Medline's prime vendor model wins market share as hospitals simplify sourcing, while bioprocessing component suppliers (WST, RGEN, AVTR) recover from the..

What this means for $RGEN

Neutral — Makes bioprocessing filtration, chromatography, and fluid management components used in biologic drug manufacturing; end markets and revenue mix have limited overlap with the hospital supply simplification and prime vendor consolidation trend.

Industry benchmark

8-name peer basket
+10.0%YTD
+12.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
134.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
2.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
8.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
1.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
9.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
2.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
50.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$0.48$0.38+26.3%
Q4 2025Feb 24, 2026$0.49$0.44+11.4%
Q3 2025Oct 28, 2025$0.46$0.42+9.5%
Q2 2025Jul 29, 2025$0.37$0.40-7.5%
Next earningsTue, Jul 28·consensus EPS $0.46

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$194.3M+14.8%50.7%9.3%$0.15$23.3M
Q4 FY25$197.9M+18.1%47.2%9.4%$0.23$17.0M
Q3 FY25$188.8M+21.9%53.2%8.9%$0.27$42.7M
Q2 FY25$182.4M+14.8%50.0%7.6%$0.26$21.0M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$822.4M$816.5M – $828.6M$2.00$1.98 – $2.0211
FY27$942.6M$931.8M – $959.0M$2.58$1.99 – $2.8514
FY28$1.1B$1.1B – $1.1B$3.28$2.51 – $4.0911
FY29$1.3B$1.2B – $1.3B$4.29$4.23 – $4.375
FY30$1.4B$1.4B – $1.5B$5.32$5.24 – $5.415

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.63%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+16.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+5.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 53.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.065-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 25Jason K GarlandCFO733 sh$106KSellApr 21Olivier LoeillotCEO3.8K sh$536K
+ 28 other (14 awards · 13 inkinds · 1 exempt) in window

See when $RGEN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteMay 158-K — Item 5.07: Shareholder vote
AI summary

RGEN held its Annual Meeting of stockholders around 2026-05-15 (8-K Item 5.07). The meeting was adjourned, likely due to insufficient quorum. Routine governance event — monitor for unusually high withhold votes as an activist signal.

+ 12 other (4 13Gs · 3 proxys · 2 earnings 8-Ks · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Repligen to Report Second Quarter 2026 Financial Resultsglobenewswire.com·3d agoHere Are Tuesday’s Best Wall Street Analyst Research Calls: Adobe, American Airlines, Broadcom, First Solar, Meta Platforms, Shopify, Space-X, Ventas, Waste Managment, and More247wallst.com·11d agoA Look at Repligen Corp (RGEN) After 4.9% Gain -- GF Value $175.89 vs Price $145.23gurufocus.com·22d agoRepligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tells Investorsgurufocus.com·25d agoRepligen Corp (RGEN) Shares Surge 3.8% -- What GF Score of 83 Tells Investorsgurufocus.com·38d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$AVTR$WST$MDLN$QDEL$WRBY$AZTA$PLSE
Voices on X · last 7 days

No standout posts about $RGEN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport